With Empower Patient Services, it’s not “1 size fits all”

Support is individualized, streamlined, and comprehensive

It’s simple—we empower patients to spend less time focused on their hereditary angioedema (HAE). It’s more than service—it’s partnership.

Empower Patient Services is known for customer service and a dedicated care team who truly care. In a qualitative research study of patients who have experience with Empower Patient Services, nearly everyone rated it 10 out of 10 for excellence.^1,a

^aThis information was collected and analyzed using a qualitative methodology and a small sample size (N=15). As with all qualitative research, caution should be taken when interpreting these findings.¹

Empower Patient Services—putting patients first

Through an exclusive specialty pharmacy provider, you will have a dedicated care team to serve as the single point of contact for you, your office staff, and your patients throughout the ORLADEYO^® journey.

No phone trees, no transfers, no handoffs—just 1 person who will assist you and your patients throughout.

One stop for all of your ORLADEYO needs

Wherever you and your patients are in the journey, your ORLADEYO care team is here to help to support your patients on therapy.

From copay assistance to ORLADEYO shipment coordination—your dedicated care team will be your resource for everything, including

Rapid therapy initiation

Quick Start program provides access to ORLADEYO during insurance approval process for all insured patients^b
On average, patients receive their first shipment of ORLADEYO in less than a week following submission of the prescription

Comprehensive financial support

Understanding benefits and insurance approval process
Reimbursement and financial assistance for all patients, regardless of insurance status
$0 copay for eligible commercially insured patients (up to the annual program maximum to cover out-of-pocket expenses per calendar year)^c

Personalized HAE and ORLADEYO support

Single point of contact for you and your patients
Customized support during transition to ORLADEYO
Coordination of deliveries
Ongoing patient support

^b Subject to terms and conditions of the Quick Start Program. BioCryst reserves the right to rescind, revoke, or amend the program at any time without notice.
^c Eligibility for copay assistance: The Co-Pay Assistance Program (the Program) is for commercially insured patients. The Program is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third-party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-payment assistance under the Program is not transferable. The Program will provide eligible patients with 100% of their copay obligations up to the annual program maximum. The Program only applies in the United States, including Puerto Rico and other US territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately at 1-866-536-7693. BioCryst reserves the right to rescind, revoke, or amend the Program at any time without notice. Additional details will be made available to qualified program participants.

Call us at 1-866-5-EMPOWER (1-866-536-7693) to speak with a care team member and learn more about the unique Empower Patient Services experience.

Ready to prescribe ORLADEYO?

Prescribe

See useful resources

INDICATION

ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

IMPORTANT SAFETY INFORMATION

An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John’s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

Reference: 1. Data on file, BioCryst Pharmaceuticals Inc.